Skyhawk Therapeutics announced that SKY-0515, an investigational oral RNA-splicing therapy for #HuntingtonDisease (HD), has met the eligibility criteria to apply for provisional approval by the Australian Therapeutic Goods Administration.
Read more: https://bit.ly/4cpZeZ6
#RareDisease #SKY0515
0
0
0
0